Browse TAF1L

Summary
SymbolTAF1L
NameTAF1 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 210kDa-like
Aliases TAF1-like RNA polymerase II, TATA box binding protein (TBP)-associated factor, 210kDa; TAF(II)210; TAF2A2; T ......
Chromosomal Location9p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus
Domain PF00439 Bromodomain
PF12157 Protein of unknown function (DUF3591)
PF09247 TATA box-binding protein binding
Function

May act as a functional substitute for TAF1/TAFII250 during male meiosis, when sex chromosomes are transcriptionally silenced.

> Gene Ontology
 
Biological Process GO:0006352 DNA-templated transcription, initiation
GO:0006354 DNA-templated transcription, elongation
GO:0006367 transcription initiation from RNA polymerase II promoter
GO:0006368 transcription elongation from RNA polymerase II promoter
GO:0006473 protein acetylation
GO:0006475 internal protein amino acid acetylation
GO:0007126 meiotic nuclear division
GO:0007140 male meiosis
GO:0016570 histone modification
GO:0016573 histone acetylation
GO:0018205 peptidyl-lysine modification
GO:0018393 internal peptidyl-lysine acetylation
GO:0018394 peptidyl-lysine acetylation
GO:0043543 protein acylation
GO:0051123 RNA polymerase II transcriptional preinitiation complex assembly
GO:0051321 meiotic cell cycle
GO:0065004 protein-DNA complex assembly
GO:0070897 DNA-templated transcriptional preinitiation complex assembly
GO:0071824 protein-DNA complex subunit organization
GO:0072331 signal transduction by p53 class mediator
GO:1901796 regulation of signal transduction by p53 class mediator
GO:1903046 meiotic cell cycle process
Molecular Function GO:0000983 transcription factor activity, RNA polymerase II core promoter sequence-specific
GO:0001075 transcription factor activity, RNA polymerase II core promoter sequence-specific binding involved in preinitiation complex assembly
GO:0001076 transcription factor activity, RNA polymerase II transcription factor binding
GO:0001083 transcription factor activity, RNA polymerase II basal transcription factor binding
GO:0001129 RNA polymerase II transcription factor activity, TBP-class protein binding, involved in preinitiation complex assembly
GO:0001132 RNA polymerase II transcription factor activity, TBP-class protein binding
GO:0004402 histone acetyltransferase activity
GO:0004674 protein serine/threonine kinase activity
GO:0008080 N-acetyltransferase activity
GO:0008134 transcription factor binding
GO:0016407 acetyltransferase activity
GO:0016410 N-acyltransferase activity
GO:0016746 transferase activity, transferring acyl groups
GO:0016747 transferase activity, transferring acyl groups other than amino-acyl groups
GO:0017025 TBP-class protein binding
GO:0034212 peptide N-acetyltransferase activity
GO:0042393 histone binding
GO:0061733 peptide-lysine-N-acetyltransferase activity
GO:0070577 lysine-acetylated histone binding
Cellular Component GO:0000428 DNA-directed RNA polymerase complex
GO:0005667 transcription factor complex
GO:0005669 transcription factor TFIID complex
GO:0016591 DNA-directed RNA polymerase II, holoenzyme
GO:0030880 RNA polymerase complex
GO:0044798 nuclear transcription factor complex
GO:0055029 nuclear DNA-directed RNA polymerase complex
GO:0061695 transferase complex, transferring phosphorus-containing groups
GO:0090575 RNA polymerase II transcription factor complex
> KEGG and Reactome Pathway
 
KEGG hsa03022 Basal transcription factors
Reactome R-HSA-1643685: Disease
R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-162906: HIV Infection
R-HSA-162587: HIV Life Cycle
R-HSA-167161: HIV Transcription Initiation
R-HSA-5663205: Infectious disease
R-HSA-162599: Late Phase of HIV Life Cycle
R-HSA-167162: RNA Polymerase II HIV Promoter Escape
R-HSA-674695: RNA Polymerase II Pre-transcription Events
R-HSA-73776: RNA Polymerase II Promoter Escape
R-HSA-73857: RNA Polymerase II Transcription
R-HSA-75953: RNA Polymerase II Transcription Initiation
R-HSA-76042: RNA Polymerase II Transcription Initiation And Promoter Clearance
R-HSA-73779: RNA Polymerase II Transcription Pre-Initiation And Promoter Opening
R-HSA-5633007: Regulation of TP53 Activity
R-HSA-6804756: Regulation of TP53 Activity through Phosphorylation
R-HSA-167172: Transcription of the HIV genome
R-HSA-3700989: Transcriptional Regulation by TP53
Summary
SymbolTAF1L
NameTAF1 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 210kDa-like
Aliases TAF1-like RNA polymerase II, TATA box binding protein (TBP)-associated factor, 210kDa; TAF(II)210; TAF2A2; T ......
Chromosomal Location9p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TAF1L and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolTAF1L
NameTAF1 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 210kDa-like
Aliases TAF1-like RNA polymerase II, TATA box binding protein (TBP)-associated factor, 210kDa; TAF(II)210; TAF2A2; T ......
Chromosomal Location9p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TAF1L in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.55 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolTAF1L
NameTAF1 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 210kDa-like
Aliases TAF1-like RNA polymerase II, TATA box binding protein (TBP)-associated factor, 210kDa; TAF(II)210; TAF2A2; T ......
Chromosomal Location9p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TAF1L in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)141201
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)6501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)8701
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.3480.622
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.0680.961
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.7160.614
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.3550.121
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.3670.422
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.3810.421
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 4801
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 2801
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0240.734
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TAF1L in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.113.7-2.61
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.116.9-5.80.747
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)2117195.913.10.355
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131123.19.1140.596
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38277.907.90.26
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221313.6013.60.279
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11139.109.10.458
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 512200200.294
Summary
SymbolTAF1L
NameTAF1 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 210kDa-like
Aliases TAF1-like RNA polymerase II, TATA box binding protein (TBP)-associated factor, 210kDa; TAF(II)210; TAF2A2; T ......
Chromosomal Location9p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TAF1L. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTAF1L
NameTAF1 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 210kDa-like
Aliases TAF1-like RNA polymerase II, TATA box binding protein (TBP)-associated factor, 210kDa; TAF(II)210; TAF2A2; T ......
Chromosomal Location9p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TAF1L. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TAF1L.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTAF1L
NameTAF1 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 210kDa-like
Aliases TAF1-like RNA polymerase II, TATA box binding protein (TBP)-associated factor, 210kDa; TAF(II)210; TAF2A2; T ......
Chromosomal Location9p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TAF1L. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTAF1L
NameTAF1 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 210kDa-like
Aliases TAF1-like RNA polymerase II, TATA box binding protein (TBP)-associated factor, 210kDa; TAF(II)210; TAF2A2; T ......
Chromosomal Location9p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TAF1L expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTAF1L
NameTAF1 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 210kDa-like
Aliases TAF1-like RNA polymerase II, TATA box binding protein (TBP)-associated factor, 210kDa; TAF(II)210; TAF2A2; T ......
Chromosomal Location9p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TAF1L and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTAF1L
NameTAF1 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 210kDa-like
Aliases TAF1-like RNA polymerase II, TATA box binding protein (TBP)-associated factor, 210kDa; TAF(II)210; TAF2A2; T ......
Chromosomal Location9p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TAF1L collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.